RNA Long Call Strategy
RNA (Atrium Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
RNA (Atrium Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $128.5M, a beta of 0.37 versus the broader market, a 52-week range of 7.47-16.77, average daily share volume of 247K, a public-listing history dating back to 2026, approximately 511 full-time employees. These structural characteristics shape how RNA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.37 indicates RNA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long call on RNA?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
RNA snapshot
As of November 13, 2026, spot at $7.66. The long call on RNA below is built from the November 13, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 63-day expiry.
Why this long call structure on RNA specifically: IV rank is unavailable in the current snapshot, so regime-based timing for RNA is inferred from ATM IV alone. The 63-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RNA expiries trade a higher absolute premium for lower per-day decay. Position sizing on RNA should anchor to the underlying notional of $7.66 per share and to the trader's directional view on RNA stock.
RNA long call setup
The RNA long call below is built from the November 13, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RNA at $7.66 on that close, the first option leg uses a $7.66 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RNA chain at a 63-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RNA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $7.66 | N/A |
RNA long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
RNA long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on RNA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on RNA
Long calls on RNA express a bullish thesis with defined risk; traders use them ahead of RNA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
RNA thesis for this long call
A RNA long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. As a Healthcare name, RNA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RNA-specific events.
RNA long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RNA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RNA alongside the broader basket even when RNA-specific fundamentals are unchanged. Long-premium structures like a long call on RNA are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current RNA chain quotes before placing a trade.
Frequently asked questions
- What is a long call on RNA?
- A long call on RNA is the long call strategy applied to RNA (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With RNA stock at $7.66 on the November 13, 2026 close, the strikes shown on this page are snapped to the nearest listed RNA chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are RNA long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the RNA long call priced from the November 13, 2026 end-of-day chain at a 30-day expiry (ATM IV the current ATM IV), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a RNA long call?
- The breakeven for the RNA long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from the November 13, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk.
- When should you consider a long call on RNA?
- Long calls on RNA express a bullish thesis with defined risk; traders use them ahead of RNA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current RNA implied volatility affect this long call?
- Current RNA ATM IV is the current ATM IV; IV rank context is unavailable in the current snapshot.